AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2011-07-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 104
- Registration Number
- NCT00502567
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
- Conditions
- Advanced Tumor
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2009-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT00502060
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands
Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer
- Conditions
- Advanced Prostate Adenocarcinoma
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00502164
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML
- Conditions
- LeukaemiaMyelocyticAcute
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT00502385
Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases
- Conditions
- Advanced Solid TumorLiver Metastases
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00501605
- Locations
- 🇩🇪
Research Site, Freiburg, Germany
Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 659
- Registration Number
- NCT00501111
- Locations
- 🇬🇧
Research Site, Swindon, United Kingdom
A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 181
- Registration Number
- NCT00500318
- Locations
- 🇺🇸
Forest Investigative Site 0974, Pensacola, Florida, United States
🇺🇸Forest Investigative Site 0988, Sacramento, California, United States
🇺🇸Forest Investigative Site 0887, Los Angeles, California, United States
A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 163
- Registration Number
- NCT00500370
- Locations
- 🇵🇷
Research Site, San Juan, Puerto Rico
AZD1152 in Patients With Advanced Solid Malignancies-Study 1
- Conditions
- Solid Tumors
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2009-06-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT00497731
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands
AZD1152 in Patients With Advanced Solid Malignancies-Study 3
- Conditions
- Solid Tumours
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2009-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT00497679
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom